Novartis Ag (NVS) 52.49 -0.26

Novartis AG ADS
(NVS) 52.49 -0.26

Last Trade:	52.00	Day Range:	51.98 - 52.59
Trade Time:	06:05PM	52wk Range:	51.20 - 63.83
Prev. Close:	52.26	Market Cap:	125.96B
Open:	52.49	Div Yield:	4.52
Volume:	2328093	PE:
EPS:	0.00

The Latest On NVS

Blueberries, Gold Bond, Ovaltine and Obesity: The Makings for a Very Good Story (Part 1) 5/23/12 5:03pm

UPDATE: Novartis Reports Decline In Q1 Profit 4/24/12 4:37am

Benzinga's M&A Chatter for Tuesday March 20, 2012 3/20/12 8:03pm

Barron's Recap: Home Prices on the Rebound, the BATS Global Markets IPO 3/18/12 11:05am

UPDATE: JP Morgan Downgrades Novartis to Neutral 3/6/12 10:49am

Benzinga's Top Downgrades 3/6/12 9:08am

Financial Breakfast: Morning News Summary for March 6, 2012 3/6/12 8:23am

UPDATE: Bank of America Downgrades Novartis to Underperform 2/6/12 10:20am

From Earlier: FDA Approves Novartis Drug Gleevec Label Recommending Extending Treatment to Three Years for Certain GIST Patients After Surgery 2/1/12 7:52am

Earnings Roundup 1/25/12 10:25am

Financial Breakfast: Morning News Summary for January 25, 2012 1/25/12 8:26am

Novartis Q4 Net Profit Drops 46% 1/25/12 4:46am

Blueberries, Gold Bond, Ovaltine and Obesity: The Makings for a Very Good Story (Part 1) 5/23/12

UPDATE: Novartis Reports Decline In Q1 Profit 4/24/12

Benzinga's M&A Chatter for Tuesday March 20, 2012 3/20/12

Barron's Recap: Home Prices on the Rebound, the BATS Global Markets IPO 3/18/12

UPDATE: JP Morgan Downgrades Novartis to Neutral 3/6/12

Benzinga's Top Downgrades 3/6/12

Financial Breakfast: Morning News Summary for March 6, 2012 3/6/12

UPDATE: Bank of America Downgrades Novartis to Underperform 2/6/12

From Earlier: FDA Approves Novartis Drug Gleevec Label Recommending Extending Treatment to Three Years for Certain GIST Patients After Surgery 2/1/12

Earnings Roundup 1/25/12

Financial Breakfast: Morning News Summary for January 25, 2012 1/25/12

Novartis Q4 Net Profit Drops 46% 1/25/12

Blueberries, Gold Bond, Ovaltine and Obesity: The Makings for a Very Good Story (Part 1) 5/23/12

Benzinga's M&A Chatter for Tuesday March 20, 2012 3/20/12

Financial Breakfast: Morning News Summary for March 6, 2012 3/6/12

Financial Breakfast: Morning News Summary for January 25, 2012 1/25/12

Benzinga's M&A Chatter for Tuesday January 17, 2012 1/17/12

Drug Failures and Firings will Hurt Novartis, But Can a Dividend Heal All Ills? 1/13/12

Stocks To Watch For January 13 1/13/12

How to Trade Biotechs Based on the JP Morgan Health Care Conference 1/11/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Will the Swiss Guide Europe? 1/9/12

Stay Safe in 2012 With These 5 Stocks 12/29/11

Best Biotech Stocks of 2011 12/27/11

UPDATE: JP Morgan Downgrades Novartis to Neutral 3/6/12

Benzinga's Top Downgrades 3/6/12

Financial Breakfast: Morning News Summary for March 6, 2012 3/6/12

UPDATE: Bank of America Downgrades Novartis to Underperform 2/6/12

Financial Breakfast: Morning News Summary for January 25, 2012 1/25/12

How to Trade Biotechs Based on the JP Morgan Health Care Conference 1/11/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Citigroup Initiates Novartis at Neutral 11/29/11

End-of-Day Market Summary for October 25, 2011 10/25/11

Hapoalim Securities Reiterates Buy Rating, $15 PT On VNDA 4/12/11

LifeTech Capital Comments On Merck Acquisition (MRK, ISPH) 4/7/11

Piper Jaffray Defends THRX Following Delayed Sell-Off 1/31/11

Trade NVS
NOW!

Partner Headlines

The Zacks Analyst Blog Highlights: Biogen, Teva Pharmaceutical, Pfizer, Novartis and U.S. Bancorp - Press Releases 5/29/12

Guru Stocks at 52-Week Lows: NVS, OGZPY, BHP, SI, PBR 5/28/12

Biogen Tysabri Canadian Label Update - Analyst Blog 5/25/12

Gen-Probe Remains Neutral - Analyst Blog 5/25/12

Incyte Stays Neutral - Analyst Blog 5/24/12

Shire Presents Data on Venvanse - Analyst Blog 5/24/12

Perrigo's Generic Portfolio Boosted - Analyst Blog 5/23/12

Guru Stocks at 52-Week Lows: NVS, BHP, SI, DCM, COP 5/22/12

Report: Drug Makers Working on Emergency Supply Plan in Greece 5/18/12

Disappointing Data on Pfizer Drug - Analyst Blog 5/16/12

Positive Data on Novartis' Lucentis - Analyst Blog 5/15/12

Press Releases

Photo Release -- Fire-Breathing Caballo Diablo Heats Up the Desert During the 2012 Moab Easter Jeep Safari 4/3/12 GlobeNewswire

GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 3/15/12 Newswire

Apricus Biosciences CEO is Interviewed on CDTV.Net 3/6/12 GlobeNewswire

University Teams Tap Mobile Phones and Social Networks to Fight Non-communicable Diseases 2/9/12 Newswire

GenVec Extends Research Collaboration with Global Pharmaceutical Company 1/27/12 Newswire

Research and Markets: Large Cap Value and Other Investing Strategies Report 12/22/11 Business Wire

Franklin Covey Co.'s 7 Habits Program Piloted and Funded by the Government of India in 20 Plus (NVS) Schools; 15,000 Teachers Trained in Additional Government Schools 12/20/11 Business Wire

GenVec Achieves Second Milestone in Collaboration 12/6/11 Newswire

Get the latest NVS stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Novartis AG ADS stock price.

Novartis AG ADS by YCharts

Novartis Ag (NVS) 52.49 -0.26

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On NVS

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social